Advertisement

Human Cell

pp 1–9 | Cite as

Evodiamine ameliorates paclitaxel-induced neuropathic pain by inhibiting inflammation and maintaining mitochondrial anti-oxidant functions

  • Peipei Wu
  • Yong ChenEmail author
Research Article
  • 12 Downloads

Abstract

Chemotherapy-induced neuropathic pain (CINP) is a common and debilitating side effect of cancer treatment. Evodiamine, a major effective compound isolated from Evodia rutaecarpa, has been associated with anti-inflammatory and anti-nociceptive effects, an important therapeutic strategy for the treatment of neuropathic pain. However, the effects of evodiamine on CINP remain unknown. Thus, this study aims to investigate the pharmacological potential of evodiamine in attenuating paclitaxel-induced peripheral neuropathy. The results showed that evodiamine enhanced but not reduced the sensitivity of cancer cells to paclitaxel treatment. In a rat model of paclitaxel-induced peripheral neuropathy, evodiamine significantly ameliorated the development of mechanical and thermal hypersensitivity. Moreover, paclitaxel-induced the loss of intraepidermal nerve fibers was markedly inhibited by evodiamine administration. This inhibitory effect was accompanied with the decrease in inflammatory and chemoattractant cytokines level in dorsal root ganglia (DRG), such as interleukin (IL)-1β, IL-6, tumor necrosis factor-α and monocyte chemoattractant protein-1. In addition, evodiamine administration limited paclitaxel-induced elevation of oxidative stress in DRG tissues. The mitochondrial dysfunction evoked by paclitaxel was also remarkably improved in evodiamine-treated rats, evidenced by restoration of peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α), uncoupling protein 2 (UCP2), and superoxide dismutase 2 (SOD2) expression. In in vitro studies, we found that evodiamine prevented paclitaxel-induced the loss of mitochondrial membrane potential and PGC-1α, UCP2 and SOD2 expression in DRG cells. In conclusion, our study demonstrates that evodiamine ameliorates paclitaxel-induced neuropathic pain by inhibiting inflammatory response and maintaining mitochondrial anti-oxidant functions, indicating that evodiamine may be a promising therapeutic agent for CINP treatment.

Keywords

Neuropathic pain Paclitaxel Evodiamine Inflammation Oxidative stress Mitochondrial dysfunction 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All animal protocols were performed according to the guidelines of the Institutional Animal Care and Use Committee of Nanjing Medical University and approved by the Institutional Animal Ethics Office.

References

  1. 1.
    Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6(12):657–66.  https://doi.org/10.1038/nrneurol.2010.160.CrossRefGoogle Scholar
  2. 2.
    Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40(7):872–82.  https://doi.org/10.1016/j.ctrv.2014.04.004.CrossRefGoogle Scholar
  3. 3.
    Smith EM, Pang H. Therapy for chemotherapy-induced peripheral neuropathy—in reply. Jama. 2013;310(5):538.  https://doi.org/10.1001/jama.2013.7905.CrossRefGoogle Scholar
  4. 4.
    Ishii N, Tsubouchi H, Miura A, Yanagi S, Ueno H, Shiomi K, et al. Ghrelin alleviates paclitaxel-induced peripheral neuropathy by reducing oxidative stress and enhancing mitochondrial anti-oxidant functions in mice. Eur J Pharmacol. 2018;819:35–42.  https://doi.org/10.1016/j.ejphar.2017.11.024.CrossRefGoogle Scholar
  5. 5.
    Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–70.  https://doi.org/10.1016/j.pain.2014.09.020.CrossRefGoogle Scholar
  6. 6.
    Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122(3):245–57.  https://doi.org/10.1016/j.pain.2006.01.037.CrossRefGoogle Scholar
  7. 7.
    Duggett NA, Griffiths LA, McKenna OE, de Santis V, Yongsanguanchai N, Mokori EB, et al. Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy. Neuroscience. 2016;333:13–26.  https://doi.org/10.1016/j.neuroscience.2016.06.050.CrossRefGoogle Scholar
  8. 8.
    Kidd JF, Pilkington MF, Schell MJ, Fogarty KE, Skepper JN, Taylor CW, et al. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem. 2002;277(8):6504–10.  https://doi.org/10.1074/jbc.M106802200.CrossRefGoogle Scholar
  9. 9.
    Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90–107.  https://doi.org/10.1016/j.neulet.2014.10.014.CrossRefGoogle Scholar
  10. 10.
    Vendrell I, Macedo D, Alho I, Dionisio MR, Costa L. Treatment of cancer pain by targeting cytokines. Mediat Inflamm. 2015;2015:984570.  https://doi.org/10.1155/2015/984570.CrossRefGoogle Scholar
  11. 11.
    Lee SH, Son JK, Jeong BS, Jeong TC, Chang HW, Lee ES, et al. Progress in the studies on rutaecarpine. Molecules. 2008;13(2):272–300.CrossRefGoogle Scholar
  12. 12.
    Yu X, Wu DZ, Yuan JY, Zhang RR, Hu ZB. Gastroprotective effect of fructus evodiae water extract on ethanol-induced gastric lesions in rats. Am J Chin Med. 2006;34(6):1027–35.  https://doi.org/10.1142/S0192415X06004491.CrossRefGoogle Scholar
  13. 13.
    Wang L, Hu CP, Deng PY, Shen SS, Zhu HQ, Ding JS, et al. The protective effects of rutaecarpine on gastric mucosa injury in rats. Planta Med. 2005;71(5):416–9.  https://doi.org/10.1055/s-2005-864135.CrossRefGoogle Scholar
  14. 14.
    Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ, Wang PS. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J Cell Biochem. 2007;101(1):44–56.  https://doi.org/10.1002/jcb.21036.CrossRefGoogle Scholar
  15. 15.
    Fei XF, Wang BX, Li TJ, Tashiro S, Minami M, Xing DJ, et al. Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci. 2003;94(1):92–8.CrossRefGoogle Scholar
  16. 16.
    Liao CH, Pan SL, Guh JH, Chang YL, Pai HC, Lin CH, et al. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis. 2005;26(5):968–75.  https://doi.org/10.1093/carcin/bgi041.CrossRefGoogle Scholar
  17. 17.
    Ogasawara M, Matsubara T, Suzuki H. Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells. Biol Pharm Bull. 2001;24(8):917–20.CrossRefGoogle Scholar
  18. 18.
    Kobayashi Y. The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpa in mice. Planta Med. 2003;69(5):425–8.  https://doi.org/10.1055/s-2003-39701.CrossRefGoogle Scholar
  19. 19.
    Jiang J, Hu C. Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa. Molecules. 2009;14(5):1852–9.  https://doi.org/10.3390/molecules14051852.CrossRefGoogle Scholar
  20. 20.
    Raymon HK, Thode S, Zhou J, Friedman GC, Pardinas JR, Barrere C, et al. Immortalized human dorsal root ganglion cells differentiate into neurons with nociceptive properties. J Neurosci. 1999;19(13):5420–8.CrossRefGoogle Scholar
  21. 21.
    Zhang X, Jiang N, Li J, Zhang D, Lv X. Rapamycin alleviates proinflammatory cytokines and nociceptive behavior induced by chemotherapeutic paclitaxel. Neurol Res. 2018.  https://doi.org/10.1080/01616412.2018.1531199.Google Scholar
  22. 22.
    Boyette-Davis J, Xin W, Zhang H, Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011;152(2):308–13.  https://doi.org/10.1016/j.pain.2010.10.030.CrossRefGoogle Scholar
  23. 23.
    Liu XJ, Zhang Y, Liu T, Xu ZZ, Park CK, Berta T, et al. Nociceptive neurons regulate innate and adaptive immunity and neuropathic pain through MyD88 adapter. Cell Res. 2014;24(11):1374–7.  https://doi.org/10.1038/cr.2014.106.CrossRefGoogle Scholar
  24. 24.
    Xu J, Zhang L, Xie M, Li Y, Huang P, Saunders TL, et al. Role of complement in a rat model of paclitaxel-induced peripheral neuropathy. J Immunol. 2018;200(12):4094–101.  https://doi.org/10.4049/jimmunol.1701716.CrossRefGoogle Scholar
  25. 25.
    Castelli V, Palumbo P, d’Angelo M, Moorthy NK, Antonosante A, Catanesi M, et al. Probiotic DSF counteracts chemotherapy induced neuropathic pain. Oncotarget. 2018;9(46):27998–8008.  https://doi.org/10.18632/oncotarget.25524.CrossRefGoogle Scholar
  26. 26.
    Ko MH, Hu ME, Hsieh YL, Lan CT, Tseng TJ. Peptidergic intraepidermal nerve fibers in the skin contribute to the neuropathic pain in paclitaxel-induced peripheral neuropathy. Neuropeptides. 2014;48(3):109–17.  https://doi.org/10.1016/j.npep.2014.02.001.CrossRefGoogle Scholar
  27. 27.
    Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3–9.  https://doi.org/10.1016/j.cyto.2012.03.027.CrossRefGoogle Scholar
  28. 28.
    Zhang H, Li Y, de Carvalho-Barbosa M, Kavelaars A, Heijnen CJ, Albrecht PJ, et al. Dorsal root ganglion infiltration by macrophages contributes to paclitaxel chemotherapy-induced peripheral neuropathy. J Pain. 2016;17(7):775–86.  https://doi.org/10.1016/j.jpain.2016.02.011.CrossRefGoogle Scholar
  29. 29.
    Ale A, Bruna J, Morell M, van de Velde H, Monbaliu J, Navarro X, et al. Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model. Exp Neurol. 2014;253:165–73.  https://doi.org/10.1016/j.expneurol.2013.12.020.CrossRefGoogle Scholar
  30. 30.
    Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, Milligan ED, et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun. 2007;21(5):686–98.  https://doi.org/10.1016/j.bbi.2006.10.012.CrossRefGoogle Scholar
  31. 31.
    Zhang X, Zhang S, Zhu S, Chen S, Han J, Gao K, et al. Identification of mitochondria-targeting anticancer compounds by an in vitro strategy. Anal Chem. 2014;86(11):5232–7.  https://doi.org/10.1021/ac500918g.CrossRefGoogle Scholar
  32. 32.
    Bernardi P, Krauskopf A, Basso E, Petronilli V, Blachly-Dyson E, Di Lisa F, et al. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J. 2006;273(10):2077–99.  https://doi.org/10.1111/j.1742-4658.2006.05213.x.CrossRefGoogle Scholar
  33. 33.
    Xiao WH, Bennett GJ. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain. 2012;153(3):704–9.  https://doi.org/10.1016/j.pain.2011.12.011.CrossRefGoogle Scholar
  34. 34.
    Wang Y, Wang C, Zhang D, Wang H, Bo L, Deng X. Dexmedetomidine protects against traumatic brain injury-induced acute lung injury in mice. Med Sci Monit. 2018;24:4961–7.  https://doi.org/10.12659/MSM.908133.CrossRefGoogle Scholar
  35. 35.
    Hu X, Jiao R, Li H, Wang X, Lyu H, Gao X, et al. Antiproliferative hydrogen sulfide releasing evodiamine derivatives and their apoptosis inducing properties. Eur J Med Chem. 2018;151:376–88.  https://doi.org/10.1016/j.ejmech.2018.04.009.CrossRefGoogle Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of AnesthesiologyThe Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical UniversityChangzhouChina

Personalised recommendations